×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALDX – aldeyra therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALDX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/22
03:53 pm
aldx
ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
High
Report
ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
3/21
01:15 pm
aldx
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX
High
Report
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX
3/20
08:16 pm
aldx
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALDX
High
Report
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALDX
3/19
09:54 pm
aldx
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
3/19
09:00 am
aldx
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky
High
Report
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky
3/18
05:28 pm
aldx
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky
High
Report
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky
3/18
01:38 pm
aldx
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA [Yahoo! Finance]
Low
Report
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA [Yahoo! Finance]
3/18
08:03 am
aldx
Aldeyra Therapeutics (ALDX) had its "neutral" rating reaffirmed by HC Wainwright. They now have a $2.00 price target on the stock, down from $10.00.
High
Report
Aldeyra Therapeutics (ALDX) had its "neutral" rating reaffirmed by HC Wainwright. They now have a $2.00 price target on the stock, down from $10.00.
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2025
04:16 pm
aldx
aldeyra therapeutics, inc.
BEAT
Report
-2.4%
aldeyra therapeutics, inc.
8/7/2025
04:03 pm
aldx
aldeyra therapeutics, inc.
BEAT
Report
1.7%
aldeyra therapeutics, inc.
5/14/2025
05:13 pm
aldx
aldeyra therapeutics, inc.
BEAT
Report
1.9%
aldeyra therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/20
04:18 pm
aldx
Form 4 Aldeyra Therapeutics, For: Mar 19 Filed by: DOUGLAS RICHARD
High
Report
Form 4 Aldeyra Therapeutics, For: Mar 19 Filed by: DOUGLAS RICHARD
3/19
05:29 pm
aldx
Form 4 Aldeyra Therapeutics, For: Mar 18 Filed by: Alfieri Michael
Medium
Report
Form 4 Aldeyra Therapeutics, For: Mar 18 Filed by: Alfieri Michael
3/17
08:39 am
aldx
Form 8-K Aldeyra Therapeutics, For: Mar 17
Low
Report
Form 8-K Aldeyra Therapeutics, For: Mar 17
2/27
05:07 pm
aldx
Form S-8 Aldeyra Therapeutics,
Medium
Report
Form S-8 Aldeyra Therapeutics,
2/27
04:47 pm
aldx
Form 10-K Aldeyra Therapeutics, For: Dec 31
Low
Report
Form 10-K Aldeyra Therapeutics, For: Dec 31
2/17
04:00 pm
aldx
Form SCHEDULE 13G/A Aldeyra Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
Low
Report
Form SCHEDULE 13G/A Aldeyra Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
12/31
05:07 pm
aldx
Form 8-K Aldeyra Therapeutics, For: Dec 23
Medium
Report
Form 8-K Aldeyra Therapeutics, For: Dec 23
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/14
Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629
27.8%
3/24 Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection 22.9%
9/9 Form 4 Aldeyra Therapeutics, For: Sep 05 Filed by: McMullin David 13.9%
4/27 Form DEF 14A Aldeyra Therapeutics, For: Jun 09 13.1%
10/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
3/26 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.0%
10/2 Form 4 Aldeyra Therapeutics, For: Sep 30 Filed by: Brady Todd C 8.1%
12/18 Form 4 Aldeyra Therapeutics, For: Dec 16 Filed by: Brady Todd C 5.9%
11/1 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update 5.0%
1/15 Form 3 Aldeyra Therapeutics, For: Jan 13 Filed by: Miller-Rich Nancy 4.2%
3/24 Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection 22.9%
9/9 Form 4 Aldeyra Therapeutics, For: Sep 05 Filed by: McMullin David 13.9%
4/27 Form DEF 14A Aldeyra Therapeutics, For: Jun 09 13.1%
10/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
3/26 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.0%
10/2 Form 4 Aldeyra Therapeutics, For: Sep 30 Filed by: Brady Todd C 8.1%
12/18 Form 4 Aldeyra Therapeutics, For: Dec 16 Filed by: Brady Todd C 5.9%
11/1 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update 5.0%
1/15 Form 3 Aldeyra Therapeutics, For: Jan 13 Filed by: Miller-Rich Nancy 4.2%
TOP News Decliners
12/3
Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease
-40.4%
3/24 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. -17.8%
3/17 Form 4 Aldeyra Therapeutics, For: Mar 16 Filed by: DOUGLAS RICHARD -15.3%
3/6 Form 4/A Aldeyra Therapeutics, For: Mar 02 Filed by: Reed Joshua -15.3%
3/12 Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones -14.2%
8/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.5%
2/24 Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day -7.3%
2/25 Form SC 13G Aldeyra Therapeutics, Filed by: Prosight Management, LP -7.0%
10/31 Form 8-K Aldeyra Therapeutics, For: Oct 31 -6.7%
4/30 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update -6.0%
3/24 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. -17.8%
3/17 Form 4 Aldeyra Therapeutics, For: Mar 16 Filed by: DOUGLAS RICHARD -15.3%
3/6 Form 4/A Aldeyra Therapeutics, For: Mar 02 Filed by: Reed Joshua -15.3%
3/12 Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones -14.2%
8/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.5%
2/24 Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day -7.3%
2/25 Form SC 13G Aldeyra Therapeutics, Filed by: Prosight Management, LP -7.0%
10/31 Form 8-K Aldeyra Therapeutics, For: Oct 31 -6.7%
4/30 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: